Prof. Dr. Hans-Ulrich Demuth

Fraunhofer Society, Institute for Cell Therapy and Immunology Leipzig, Institute of Bioanalytics and Bioprocesses Potsdam-Golm, Germany

More than 35 years academic and industrial experience in target validation and drug discovery.

Research focussing on bioorganic mechanisms, enzyme-inhibition and protein-ligand interactions.

We discovered the therapeutic principle of Dipeptidyl Peptidase 4-inhibition as treatment for Type 2 Diabetes between 1993 and 2004, which is now on the market by pharma companies.

At the end of the last century we discovered that modification of N-terminal Glu-Aβ peptides and the Glu-BRI peptides is not sporadic, but an enzyme-catalyzed process driven by the enzyme Glutaminyl Cyclase (QC). QC and its sister enzyme isoQC are also responsible for the bioactivation of chemokines such as CCL2. Since then, both enzymes are drug targets to develop therapeutics for Alzheimer’s and other inflammatory disorders. First NCEs of the 2002 initiated Drug Discovery program entered clinics phase 2 in 2015. Now, we focus on further targets to fight neurodegeneration and inflammation.

other speakers